Expectations?None. Every trial over the last 10 years has had "good safety data." Trial results - interim or later/final (BRACELET-1) - spark some results share price-wise but I only for a day or two.
The ONLY thing that will spark ANY kind of significant share price increase will be a biz dev announcement of a partnership or buyout. I'd be willing to bet a 50% CR from a trial would do little.
Big Pharma has done more with lesser advanced trials with other biotech devs than anything with ONC. For whatever reason, there seems to be little interest beyond curiosity with BP. Every single quarter ONC is meeting with these analysts, or hobnobbing with industry folk at that conference, or presenting posters there, with no results worth noting. Every. Single. Quarter.
We have a great - a fantastic - idea/product but no one else is excited about it. I mean what more do we need to show... to prove?
Yeah, I'm flabbergasted.